Neuropace Inc (NPCE) — SEC Filings
Neuropace Inc (NPCE) — 35 SEC filings. Latest: 4 (Mar 24, 2026). Includes 19 8-K, 8 SC 13G/A, 3 10-Q.
View Neuropace Inc on SEC EDGAR
Overview
Neuropace Inc (NPCE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Mar 24, 2026: This Form 4 filing indicates that Uri Geiger, a reporting person for NeuroPace Inc., filed a statement of changes in beneficial ownership of securities on March 24, 2026, for a transaction that occurred on March 20, 2026. While the specific transaction details (buy/sell, quantity, price) are not pro
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 33 neutral, 2 mixed. The dominant filing sentiment for Neuropace Inc is neutral.
Filing Type Overview
Neuropace Inc (NPCE) has filed 2 4, 3 10-Q, 19 8-K, 2 DEF 14A, 8 SC 13G/A, 1 10-K with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of NPCE's 25 recent filings, 1 were flagged as high-risk, 9 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $27.35M |
| Net Income | $-3.50M |
| EPS | $-0.11 |
| Debt-to-Equity | 4.80 |
| Cash Position | $60.0M |
| Operating Margin | -9.5% |
| Total Assets | $107.26M |
| Total Debt | $58.75M |
Key Executives
- Uri Geiger
- Rakhi Kumar
- Renee Ryan
- Abigail P. Johnson
Industry Context
NeuroPace operates in the highly specialized and regulated neuromodulation device market. This sector is characterized by significant R&D investment, long product development cycles, and a strong reliance on clinical evidence for market adoption and reimbursement. Key trends include the increasing demand for minimally invasive procedures and the development of advanced therapies for neurological disorders.
Top Tags
8-K (8) · corporate-governance (5) · financials (4) · medical-devices (4) · Medical Devices (3) · regulation-fd (3) · sec-filing (3) · filing (3) · institutional-ownership (3) · amendment (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue for Q3 2025 | $27.35M | Increased from $21.06M in Q3 2024, a 29.8% increase. |
| Revenue for nine months ended Sep 30, 2025 | $73.40M | Increased from $58.44M in the prior year, a 25.6% increase. |
| Net loss for Q3 2025 | $3.50M | Improved from a $5.45M loss in Q3 2024. |
| Accumulated deficit as of Sep 30, 2025 | $549.69M | Indicates significant historical losses. |
| Cash, cash equivalents, and short-term investments as of Sep 30, 2025 | $60.0M | Crucial for meeting liquidity covenants. |
| Net proceeds from follow-on offering in Feb 2025 | $69.7M | Used to bolster capital and repurchase shares. |
| Amount used to repurchase shares from KCK Ltd. | $49.5M | Repurchased 5,270,845 shares at $9.40 per share. |
| Cash used in operating activities for nine months ended Sep 30, 2025 | $11.5M | Reduced from $13.2M in the prior year, showing improved operational efficiency. |
| Shares of common stock outstanding as of Oct 31, 2025 | 33,307,734 | Reflects recent equity activities. |
| Q2 2025 Revenue | $16.5M | 19.6% increase from Q2 2024's $13.8M |
| H1 2025 Revenue | $32.1M | 17.5% increase from H1 2024's $27.3M |
| Q2 2025 Net Loss | -$17.2M | Narrows from -$18.1M in Q2 2024 |
| H1 2025 Net Loss | -$35.0M | Narrows from -$36.2M in H1 2024 |
| Q2 2025 R&D Expenses | $10.1M | Continued investment in product development |
| Q2 2025 SG&A Expenses | $20.2M | Significant operational cost |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a passive investment stance in NeuroPace Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
- {"claim":"The minor reduction in stake will not significantly impact NeuroPace Inc.'s stock price in the short term.","entity":"NeuroPace Inc.","targetDate":"2024-05-09","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Neuropace Inc (NPCE)?
Neuropace Inc has 35 recent SEC filings from Jan 2024 to Mar 2026, including 19 8-K, 8 SC 13G/A, 3 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NPCE filings?
Across 35 filings, the sentiment breakdown is: 33 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Neuropace Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Neuropace Inc (NPCE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Neuropace Inc?
Key financial highlights from Neuropace Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for NPCE?
The investment thesis for NPCE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Neuropace Inc?
Key executives identified across Neuropace Inc's filings include Uri Geiger, Rakhi Kumar, Renee Ryan, Abigail P. Johnson.
What are the main risk factors for Neuropace Inc stock?
Of NPCE's 25 assessed filings, 1 were flagged high-risk, 9 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Neuropace Inc?
Recent forward-looking statements from Neuropace Inc include guidance on {"claim":"FMR LLC will maintain a passive investment stance in NeuroPace Inc. for the foreseeable future.","entity":"FMR and 1 other predictions.